OMRF has entered a license agreement with Shanghai RAAS Blood Products for development of novel hemophilia treatment.
OMRF collaborates with GSK to develop novel treatments for severe inflammatory diseases
This collaboration is part of GSK’s “Discovery Partnerships with Academia” (DPAc) efforts.
OMRF shares in $23.8 million grant to research trauma
Trauma is a leading cause of death in people under age 34.
Activated Protein C might protect kidneys from diabetes
Increased ACP could slow or stop diabetic nephropathy, which kills kidney cells.